Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses
Viruses · 2024
DOI: 10.3390/v16111776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Harry Ridgway und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC 8001, Australia. Hauptthemen laut MEDLINE: Antiviral Agents, Arginine, SARS-CoV-2, Molecular Docking Simulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, and respiratory syncytial virus (RSV) are significant global health threats. The need for low-cost, easily synthesized oral drugs for rapid deployment during outbreaks is crucial. Broad-spectrum therapeutics, or pan-antivirals, are designed to target multiple viral pathogens simultaneously by focusing on shared molecular features, such as common metal cofactors or conserved residues in viral catalytic domains. This study introduces a new generation of potent sartans, known as bisartans, engineered in our laboratories with negative charges from carboxylate or tetrazolate groups. These anionic tetrazoles interact strongly with cationic arginine residues or metal cations (e.g., Zn2+) within viral and host target sites, including the SARS-CoV-2 ACE2 receptor, influenza H1N1 neuraminidases, and the RSV fusion protein. Using virtual ligand docking and molecular dynamics, we investigated how bisartans and their analogs bind to these viral receptors, potentially blocking infection through a pan-antiviral mechanism. Bisartan, ACC519TT, demonstrated stable and high-affinity docking to key catalytic domains of the SARS-CoV-2 NSP3, H1N1 neuraminidase, and RSV fusion protein, outperforming FDA-approved drugs like Paxlovid and oseltamivir. It also showed strong binding to the arginine-rich furin cleavage sites S1/S2 and S2′, suggesting interference with SARS-CoV-2’s spike protein cleavage. The results highlight the potential of tetrazole-based bisartans as promising candidates for developing broad-spectrum antiviral therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC 8001, Australia.
- THERAmolecular, LLC, Rodeo, NM 88056, USA.
- School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, VIC 3083, Australia.
- Institute for Health and Sport, Immunology and Translational Research Group, Victoria University, Werribee, Melbourne, VIC 3030, Australia.
- Pepmetics Inc., 772 Murphy Place, Victoria, BC V6Y 3H4, Canada.
- Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
ORCID-Profile: Vasso Apostolopoulos, Laura Kate Gadanec, Jordan Swiderski, Sotirios Tsiodras, Christos T Chasapis, John M Matsoukas
Zitieren
APA
Ridgway, H., Apostolopoulos, V., Moore, G. J., Gadanec, L. K., Zulli, A., Swiderski, J., Tsiodras, S., Kelaidonis, K., Chasapis, C. T., & Matsoukas, J. M. (2024). Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses. Viruses. https://doi.org/10.3390/v16111776
Vancouver
Ridgway H, Apostolopoulos V, Moore GJ, Gadanec LK, Zulli A, Swiderski J, et al. Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses. Viruses. 2024. doi:10.3390/v16111776
BibTeX
@article{Ridgway2024,
author = {Ridgway, Harry and Apostolopoulos, Vasso and Moore, Graham J and Gadanec, Laura Kate and Zulli, Anthony and Swiderski, Jordan and Tsiodras, Sotirios and Kelaidonis, Konstantinos and Chasapis, Christos T and Matsoukas, John M},
title = {Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16111776}
}
EUVIMED